Figure 5.

Survival Monitoring of Orthotopic U87MG-Luc Glioblastoma-Bearing Mice Treated with biRGD-siPIK3CB

Animals were injected intravenously over a 48-hr interval with the following treatments, which were all mixed with Gelofusine (4 mg/20 g): saline group, biRGD-siNC (3 nmol/20 g) group, or biRGD-siPIK3CB (3 nmol/20 g) group. (A) Body weight of mice in all groups. Body weight of mice was measured daily until mice lost 40% of their primary body weight without glioblastoma, or animal deaths occurred in any group. (B) Tumor growth was monitored on days 0, 7, and 28 after treatment detected by IVIS luminescent imaging. (C) The survival curve of mice in all groups. *p < 0.05 versus saline group, ^#p < 0.05 versus biRGD-siNC group.